A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Inhaled Version of Antiviral Drug to Begin Human Testing


Clinical trials on an inhaled type of the antiviral treatment remdesivir will start on patients with COVID-19 beginning in August. Phase 1 trials on healthy volunteers will begin the week of June 22. Made by Gilead Sciences Inc, remdesivir is currently administered intravenously. The switch to a nebulizer version, which eases application, may broaden its reach.

Randomized controlled trials have shown that the drug decreased recovery time among hospitalized patients with COVID-19 by 4 days, and that patients with moderate illness did better after taking remdesivir than those who received different treatments.  Read more here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy